JOP20200252A1 - مركبات مساعدة لعامل تمايز النمو 15 وطرق استخدامها - Google Patents
مركبات مساعدة لعامل تمايز النمو 15 وطرق استخدامهاInfo
- Publication number
- JOP20200252A1 JOP20200252A1 JOP/2020/0252A JOP20200252A JOP20200252A1 JO P20200252 A1 JOP20200252 A1 JO P20200252A1 JO P20200252 A JOP20200252 A JO P20200252A JO P20200252 A1 JOP20200252 A1 JO P20200252A1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds
- methods
- same
- differentiation factor
- agonist compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 229940124085 Growth differentiation factor 15 agonist Drugs 0.000 title 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 abstract 1
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
يتعلق الاختراع الحالي بتوفير مركبات في هذه الوثيقة التي تحث على فقدان الوزن والتي تعالج مرض السكري، اختلال الشحوم في الدم، NASH و/أو السمنة. كما يتم توفير تركيبات صيدلية تحتوي على مثل هذه المركبات والاستخدامات العلاجية لتلك المركبات والتركيبات، حيث تعمل هذه المركبات كعوامل مساعدة لـ GDF15 ممتدة المفعول وخصائص مفيدة أخرى.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862653759P | 2018-04-06 | 2018-04-06 | |
PCT/US2019/024756 WO2019195091A1 (en) | 2018-04-06 | 2019-03-29 | Growth differentiation factor 15 agonist compounds and methods of using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JOP20200252A1 true JOP20200252A1 (ar) | 2020-10-04 |
JOP20200252B1 JOP20200252B1 (ar) | 2023-09-17 |
Family
ID=66630339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2020/0252A JOP20200252B1 (ar) | 2018-04-06 | 2019-03-29 | مركبات مساعدة لعامل تمايز النمو 15 وطرق استخدامها |
Country Status (28)
Country | Link |
---|---|
US (1) | US11104711B2 (ar) |
EP (1) | EP3774860B1 (ar) |
JP (1) | JP7064618B2 (ar) |
KR (1) | KR102501922B1 (ar) |
CN (1) | CN112004821B (ar) |
AR (1) | AR115021A1 (ar) |
AU (1) | AU2019248535B2 (ar) |
BR (1) | BR112020017256A2 (ar) |
CA (1) | CA3096375C (ar) |
CL (1) | CL2020002564A1 (ar) |
CO (1) | CO2020012403A2 (ar) |
CR (1) | CR20200454A (ar) |
DO (1) | DOP2020000157A (ar) |
EA (1) | EA202092084A1 (ar) |
EC (1) | ECSP20062930A (ar) |
ES (1) | ES2937049T3 (ar) |
IL (1) | IL276980A (ar) |
JO (1) | JOP20200252B1 (ar) |
MA (1) | MA52228A (ar) |
MX (1) | MX2020010370A (ar) |
PE (1) | PE20212133A1 (ar) |
PH (1) | PH12020551656A1 (ar) |
SA (1) | SA520420287B1 (ar) |
SG (1) | SG11202009853VA (ar) |
TW (1) | TWI724392B (ar) |
UA (1) | UA127545C2 (ar) |
WO (1) | WO2019195091A1 (ar) |
ZA (1) | ZA202005385B (ar) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5977814B2 (ja) | 2011-04-08 | 2016-08-24 | アムジエン・インコーポレーテツド | 増殖分化因子15(gdf−15)を使用して代謝障害を治療または改善する方法 |
EP3027642B1 (en) | 2013-07-31 | 2020-08-19 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) constructs |
AU2019253462A1 (en) | 2018-04-09 | 2020-11-26 | Amgen Inc. | Growth differentiation factor 15 fusion proteins |
US20230210950A1 (en) | 2019-10-04 | 2023-07-06 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
CN114555792A (zh) | 2019-10-15 | 2022-05-27 | 伊莱利利公司 | 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系 |
AU2022333099A1 (en) | 2021-08-24 | 2024-02-08 | Sunshine Lake Pharma Co., Ltd. | Gdf15 fusion proteins and uses thereof |
WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
WO2005113585A2 (en) | 2004-05-20 | 2005-12-01 | Acceleron Pharma Inc. | Modified tgf-beta superfamily polypeptides |
US20060074225A1 (en) | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
EP3473261A1 (en) * | 2010-05-21 | 2019-04-24 | XL-protein GmbH | Biosynthetic proline/alanine random coil polypeptides and their uses |
JP6161541B2 (ja) * | 2011-02-03 | 2017-07-12 | ゾーマ テクノロジー リミテッド | 細菌中の機能的タンパク質発現を向上させるための方法および物質 |
BR112014018575A2 (pt) * | 2012-01-26 | 2017-07-04 | Amgen Inc | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) |
WO2013148117A1 (en) | 2012-03-27 | 2013-10-03 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
US9175076B2 (en) * | 2012-12-21 | 2015-11-03 | Aveo Pharmaceuticals, Inc. | Anti-GDF15 antibodies |
BR112015018104A2 (pt) | 2013-01-30 | 2017-11-21 | Ngm Biopharmaceuticals Inc | polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições |
EP3027647A4 (en) | 2013-07-31 | 2017-01-04 | Amgen Inc. | Stabilization of fc-containing polypeptides |
EP3027642B1 (en) | 2013-07-31 | 2020-08-19 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) constructs |
EP3157947A1 (en) | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
SG11201609706VA (en) | 2014-06-23 | 2017-01-27 | Novartis Ag | Site specific protein modifications |
RU2017101436A (ru) | 2014-06-24 | 2018-07-24 | Ново Нордиск А/С | Mic-1 слитные белки и их применение |
WO2016018931A1 (en) | 2014-07-30 | 2016-02-04 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
AU2015339134B2 (en) | 2014-10-30 | 2021-06-17 | Acceleron Pharma Inc. | Methods and compositions using GDF15 polypeptides for increasing red blood cells |
PE20171058A1 (es) * | 2014-10-31 | 2017-07-21 | Ngm Biopharmaceuticals Inc | Composiciones y metodos de uso para tratar trastornos metabolicos |
WO2016131893A1 (en) | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
KR20170134542A (ko) | 2015-04-02 | 2017-12-06 | 얀센 바이오테크 인코포레이티드 | 프로톡신-ii 변이체 및 사용 방법 |
CN108367053A (zh) * | 2015-12-22 | 2018-08-03 | 诺华股份有限公司 | 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法 |
US11105818B2 (en) | 2016-01-15 | 2021-08-31 | Novo Nordisk A/S | MIC-1 receptor and uses thereof |
WO2017147742A1 (en) | 2016-02-29 | 2017-09-08 | Eli Lilly And Company | Gfral receptor therapies |
BR112018076290A2 (pt) | 2016-02-29 | 2019-11-12 | Huawei Tech Co Ltd | método de otimização de video, equipamento do usuário, dispositivo de rede e meio legível por computador |
EP3423097A4 (en) | 2016-03-04 | 2019-08-21 | NGM Biopharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR MODULATING BODY WEIGHT |
US10336812B2 (en) | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
-
2019
- 2019-03-26 TW TW108110400A patent/TWI724392B/zh active
- 2019-03-27 AR ARP190100774A patent/AR115021A1/es unknown
- 2019-03-29 KR KR1020207027912A patent/KR102501922B1/ko active IP Right Grant
- 2019-03-29 US US16/369,096 patent/US11104711B2/en active Active
- 2019-03-29 ES ES19725879T patent/ES2937049T3/es active Active
- 2019-03-29 CR CR20200454A patent/CR20200454A/es unknown
- 2019-03-29 CA CA3096375A patent/CA3096375C/en active Active
- 2019-03-29 JP JP2020554477A patent/JP7064618B2/ja active Active
- 2019-03-29 AU AU2019248535A patent/AU2019248535B2/en active Active
- 2019-03-29 BR BR112020017256-1A patent/BR112020017256A2/pt unknown
- 2019-03-29 CN CN201980024748.6A patent/CN112004821B/zh active Active
- 2019-03-29 PE PE2020001334A patent/PE20212133A1/es unknown
- 2019-03-29 EA EA202092084A patent/EA202092084A1/ru unknown
- 2019-03-29 MA MA052228A patent/MA52228A/fr unknown
- 2019-03-29 JO JOP/2020/0252A patent/JOP20200252B1/ar active
- 2019-03-29 EP EP19725879.1A patent/EP3774860B1/en active Active
- 2019-03-29 MX MX2020010370A patent/MX2020010370A/es unknown
- 2019-03-29 WO PCT/US2019/024756 patent/WO2019195091A1/en active Application Filing
- 2019-03-29 SG SG11202009853VA patent/SG11202009853VA/en unknown
- 2019-03-29 UA UAA202005772A patent/UA127545C2/uk unknown
-
2020
- 2020-08-17 DO DO2020000157A patent/DOP2020000157A/es unknown
- 2020-08-27 IL IL276980A patent/IL276980A/en unknown
- 2020-08-28 ZA ZA2020/05385A patent/ZA202005385B/en unknown
- 2020-10-01 CO CONC2020/0012403A patent/CO2020012403A2/es unknown
- 2020-10-02 CL CL2020002564A patent/CL2020002564A1/es unknown
- 2020-10-05 EC ECSENADI202062930A patent/ECSP20062930A/es unknown
- 2020-10-06 PH PH12020551656A patent/PH12020551656A1/en unknown
- 2020-10-06 SA SA520420287A patent/SA520420287B1/ar unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551656A1 (en) | Growth differentiation factor 15 agonist compounds and methods of using the same | |
GEP20207158B (en) | Amide-substituted pyridinyltriazole derivatives and uses thereof | |
MX2021007184A (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida aprocitentan. | |
PH12020551304A1 (en) | Novel crystalline forms | |
SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
NZ751746A (en) | Combination therapy with controlled-release cnp agonists | |
NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
MX2021002916A (es) | Pirfenidona enriquecida con deuterio y métodos para su uso. | |
MX2020005841A (es) | Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6. | |
MX2020013208A (es) | Composiciones herbicidas. | |
MY200161A (en) | Bacteria for targeting tumors and treating cancer | |
WO2018178243A3 (en) | Dihydrotetrabenazine for use in the treatment a movement disorder | |
MX2020013209A (es) | Composiciones herbicidas. | |
PH12021550122A1 (en) | Solubilized apyrases, methods and use | |
MX2020003185A (es) | Nuevos compuestos heterociclicos. | |
PH12019501252A1 (en) | Compositions and methods related to pyridinoylpiperidine 5-htif agonists | |
MX2021015333A (es) | Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
PH12021551091A1 (en) | Monohydrate potassium salt of a thienopyridone derivative and its preparation process | |
MX2020008082A (es) | Compuestos y composiciones para el tratamiento del dolor. | |
EA202190045A1 (ru) | Составы/композиции, содержащие ибрутиниб | |
WO2018042255A3 (en) | Nutritional compositions and use thereof | |
WO2020118199A3 (en) | Compositions and methods for treating or preventing nash, nafld, diabetes, atherosclerosis, and/or obesity | |
JOP20180070B1 (ar) | مثبطات إنزيم كيناز بروتين يتفاعل مع مستقبل 1 | |
MX2019001981A (es) | Agonista de ppary para el tratamiento de trastornos oseos. |